- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Top 5 Most-Read Conference Coverage of 2025
Our top conference coverage of the year highlighted findings presented at CROI 2025, ACCC Spring, and EHA, among others.
The top conference coverage published on AJMC.com in 2025 came from several conferences held throughout the year, with content from the European Hematological Association (EHA) Congress, the Association of Cancer Care Centers (ACCC) Conference, and the Conference on Retroviruses and Opportunistic Infections (CROI) among the most popular this year.
These are the highlights from conference coverage delivered throughout the year.
Session coverage and interviews focused on the evolving landscape of health care innovation and policy. | Image credit: © kasto – stock.adobe.com
5. Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD
In a video interview, Matthew Matasar, MD, chief of blood disorders at Rutgers Cancer Institute, spoke about his plenary presentation at the 2025 EHA Congress, which presented the findings of the phase 3 POLARGO trial. The trial evaluated the efficacy and safety of using polatuzumab vedotin in combination with rixutimab, gemcitabine, and oxaliplatin for patients who were transplant-ineligible and had relapsed/refractory diffuse large B-cell lymphoma. This regimen was compared against rituximab, gemcitabine, and oxaliplatin alone. The study found that the polatuzumab vedotin combination translated to a 40% lower risk of death in patients treated with it. Overall and progression-free survival also improved.
4. Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
Improving adherence to chronic therapies, including oral anticoagulants and oral anti–prostate cancer medication, is reliant on implementing proactive strategies like shared decision-making, clear communication, standardized documentation, and multidisciplinary collaboration. According to presentations at the American Medical Group Association Annual Conference, shared decision-making can help to align different therapies to what patients can afford and their own schedules, all of which starts at the first instance of prescribing. This can help to counteract the finding that adjusted odds of adherence to oral anticoagulants were 16% lower in men, 55% lower in patients with Medicare Part D vs commercial insurance, and 24% lower in patients who had atrial fibrillation.
3. High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
Personalized, evidence-based treatment strategies were the highlight of the American College of Cardiology Annual Scientific Session in 2025. New data on the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors included results from the SOUL trial (NCT03914326), which confirmed that oral semaglutide had cardiovascular benefits, and the STRIDE (NCT04560998), WARRIOR (NCT03417388), and DapaTAVI (NCT04696185) trials demonstrating progress in treating patients with peripheral artery disease. Experts discussed in a video interview their individual highlights of the conference and how these results will affect their practice when they return to their places of work.
2. Barrett and Zon: Lessons in Leadership, Challenges in Cancer Care
Nadine Barrett, PhD, MS, MPH, former president of ACCC, and Robin Zon, MD, FACP, FASCO, president of the American Society of Clinical Oncology, sat down for a Q&A at the ACCC meeting to discuss lessons in leadership and the future of cancer care. Barrett discussed building a team around her that can both do the job and complement each other, with team members that possess unique traits that the rest of the team lacks, whether tactical skills or emotional intelligence. Both women spoke about having to carve their own path, as they were the first in their families to go through graduate school and, in Zon’s case, among the few women who went to college at all. Both ended with a call to action to keep the fight against cancer going, noting that it will require a team of experts to overcome.
1. CROI to Present New Insights on Long COVID, HIV Cure
In a video interview set to preview the CROI 2025 conference, Annie Antar, MD, PhD, a virologist and physician-scientist at Johns Hopkins Medicine, spoke with The American Journal of Managed Care® about the 2 studies she would be presenting at the conference that focused on long COVID. Slower viral clearance of COVID-19 was associated with the development of long COVID. Slower viral clearance was associated with having more symptoms of COVID-19 and there was an association between viral rebound and higher risk of developing long COVID that was found in her research. Antar also spoke about the sessions she was interested in attending while participating at CROI 2025.
Elevating Equitable Health Care for the LGBTQ+ Community
June 18th 2024For the third episode in our special Pride Month series, we speak with Patrick McGovern, CEO of Callen-Lorde since August of 2023 and an outspoken advocate for HIV; lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+); and community health.
Listen
Community Outreach Is Enabling CeSHHAR to Close HIV Care Gaps in Zimbabwe
April 6th 2021The Centre for Sexual Health and HIV/AIDS Research Zimbabwe conducts evidence-based research related to HIV and AIDS, as well as provides and implements sexual and reproductive health education and interventions among sex workers, children, and adolescents, and in the area of masculinity.
Listen
